10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Infectious diseases company Aridis Pharmaceuticals closed nearly 7% down on Tuesday following the failure of AR-105 in a Phase II study in ventilator-associated pneumonia (VAP) caused by gram-negative Pseudomonas aeruginosa. 4 September 2019
Regenxbio today announced exclusive worldwide option and license agreement with Clearside Biomedical for evaluation of in-office delivery platform of RGX-314 to the suprachoroidal space in the eye for the treatment of wet age-related macular degeneration (wet AMD). 4 September 2019
The US Department of Health and Human Services (HHS) has committed to buying large volumes of a smallpox vaccine called ACAM2000 as part of its preparedness efforts against biodefense threats. 4 September 2019
Chugai Pharmaceutical has announced the launch of Rozlytrek (entrectinib), an anticancer agent/tyrosine kinase inhibitor, for the treatment of NTRK fusion-positive advanced or recurrent solid tumors. 4 September 2019
China’s National Medical Products Administration (NMPA) has granted marketing authorization for Tagrisso (osimertinib) as a first-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have the genetic mutations of epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions. 4 September 2019
Around the world, life expectancy continues to increase while birth rates fall, leading to aging populations that are increasingly vulnerable to dementia. 4 September 2019
US drugmaker Vertex Pharmaceuticals has taken another gamble outside its traditional cystic fibrosis specialty, this time with the aim of developing curative cell-based treatments for type 1 diabetes. 3 September 2019
Shares of US biotech Cidara Therapeutics rocketed 79% to $3.01 in active pre-market trading this morning, after announcing a partnership with UK-based Mundipharma with a total potential value of $568 million to Cidara. 3 September 2019
Germany-based biotech Velabs Therapeutics has agreed a deal with alytas therapeutics to jointly develop modulatory and functional antibodies for a novel immune-based therapy against obesity. 3 September 2019
The Indian medicines regulator has approved a novel biologic, Twinrab (rabimabs), in combination with a rabies vaccine, for rabies post-exposure prophylaxis. 3 September 2019
Detailed results have been presented by The Medicines Company from the ORION-11 trial evaluating the efficacy, safety, and tolerability of inclisiran to decrease LDL-cholesterol (LDL-C) through twice-yearly dosing. 3 September 2019
UK biotech start-up Achilles Therapeutics says it has closed a £100 million ($120.6 million) Series B financing led by incoming US investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group. 3 September 2019
UK-based drugmaker AstraZeneca has presented detailed results from the Phase III DAPA-HF trial of Farxiga (dapagliflozin) at the ESC Congress 2019 in Paris. 3 September 2019
Privately-held German biotech and radiopharmaceutical group ITM Isotopen Technologien München has agreed with DuChemBio (DCB) for the Korean company to develop and commercialize Solucin (177Lu-edotreotide) targeted radionuclide therapy (TRT) in South Korea. 2 September 2019
Astellas Pharma today revealed a worldwide licensing agreement with Japanese research organization RIKEN for the research, development and commercialization of cell therapy formulations applying RIKEN’s artificial adjuvant vector cell (aAVC) technology in oncology. 2 September 2019
Shares of US biotech firm Alexion Pharmaceuticals crashed 8% in pre-market trading on Friday, reacting to the news that peer Amgen is challenging of three patents covering top seller Soliris (eculizumab). 31 August 2019
Immunicum failed to show superiority in 18-month survival rates by adding its off-the-shelf cell therapy ilixadencel to Pfizer’s Sutent (sunitinib) in metastatic renal cell carcinoma, according to Phase II results. 30 August 2019
Shares in Swiss pharma giant Novartis were 1.7% higher after two hours of trading on Friday following the company’s presentation of Phase III data on its multiple sclerosis (MS) prospect, ofatumumab. 30 August 2019
Following on from big-selling Herceptin (trastuzumab), Roche could have another big player in breast cancer, in the shape of its PD-L1 inhibitor Tecentriq (atezolizumab). 29 August 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024